
Terns Pharmaceuticals, Inc.NASDAQ - TERN
Reports
Search reports
Name | Reporting Date | Filing Date |
---|
2024-09-30 10-Q | 2024-09-30 | 2024-11-12 |
2024-06-30 10-Q | 2024-06-30 | 2024-08-05 |
2024-03-31 10-Q | 2024-03-31 | 2024-05-13 |
2023-12-31 10-K | 2023-12-31 | 2024-03-14 |
2023-09-30 10-Q | 2023-09-30 | 2023-11-14 |
2023-06-30 10-Q | 2023-06-30 | 2023-08-08 |
2023-03-31 10-Q | 2023-03-31 | 2023-05-15 |
2022-12-31 10-K | 2022-12-31 | 2023-03-27 |
2022-09-30 10-Q | 2022-09-30 | 2022-11-09 |
2022-06-30 10-Q | 2022-06-30 | 2022-08-08 |
2022-03-31 10-Q | 2022-03-31 | 2022-05-16 |
2021-12-31 10-K | 2021-12-31 | 2022-03-07 |
2021-09-30 10-Q | 2021-09-30 | 2021-11-15 |
2021-06-30 10-Q | 2021-06-30 | 2021-08-16 |
2021-03-31 10-Q | 2021-03-31 | 2021-05-14 |
2020-12-31 10-K | 2020-12-31 | 2021-03-30 |
1
20 / page
About
Name
Terns Pharmaceuticals, Inc.
Overview
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Show More
CEO
Ms. Amy L. Burroughs M.B.A.
Industry
Biotechnology
Exchange
NASDAQ
Listing Date
2021-02-05
Address
1065 East Hillsdale Boulevard, Suite 100, Foster City, CA, 94404, United States
Tel
650-525-5535
Website